Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 4/20 | 0.45 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.45 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2898644 | 0.88 | KMT2A (0.73) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL793384 | 0.88 | KMT2A (0.85) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL20849976 | 0.84 | KMT2A (0.74) | KMT2AEPHX2TLR2TLR1CASP3 | |
| SCHEMBL8815097 | 0.83 | KMT2A (0.70) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL35211560 | 0.83 | KMT2A (0.70) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL178892 | 0.83 | KMT2A (1.00) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL178895 | 0.83 | KMT2A (1.00) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL25143 | 0.83 | KMT2A (1.00) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL178890 | 0.83 | KMT2A (1.00) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL178894 | 0.83 | KMT2A (1.00) | KMT2AEPHX2TLR2TLR1FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023378-B2 | Covalently linked antigen-antibody conjugates | HOFFMANN-LA ROCHE INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-11273223-B2 | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles | HOFFMANN-LA ROCHE INC. (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3960768-A1 | BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | F. Hoffmann-La Roche AG (CH) | 2022-03-02 | — | — | EP | disclosed |
| EP-3089996-B1 | BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | HOFFMANN LA ROCHE (CH) | 2021-07-28 | — | — | EP | disclosed |
| US-20210069338-A1 | BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | HOFFMANN-LA ROCHE INC. | 2021-03-11 | — | — | US | disclosed |
| EP-3138580-B1 | COVALENTLY LINKED ANTIGEN-ANTIBODY CONJUGATES | HOFFMANN LA ROCHE (CH) | 2021-03-03 | — | — | EP | disclosed |
| US-10806795-B2 | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles | HOFFMANN-LA ROCHE INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200164064-A1 | COVALENTLY LINKED ANTIGEN-ANTIBODY CONJUGATES | HOFFMANN-LA ROCHE INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10561737-B2 | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles | HOFFMANN-LA ROCHE INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-9629934-B2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | DYAX CORP. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20050147555-A1 | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same | BRACCO SUISSE SA (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050100963-A1 | Multimeric protein comprising endothelial growth factor (VEGF) and kinase domain region (KDR) for use in detection, prevention and treatment of cell proliferative, virral and infectious disorders | DYAX CORPORATION (US) | 2005-05-12 | — | — | US | disclosed |
| US-20050027105-A9 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | BRACCO SUISSE SA (CH) | 2005-02-03 | — | — | US | disclosed |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | ARBOGAST CHRISTOPHE (FR) | 2004-10-21 | — | — | US | disclosed |
| WO-2004065621-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | DYAX CORP. (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040018974-A1 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2004-01-29 | — | — | US | disclosed |
| WO-2003074005-A2 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | DYAX CORP. (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-1289565-A2 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS | Bracco Research USA (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020147136-A1 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO SUISSE SA (CH) | 2002-10-10 | — | — | US | disclosed |
| WO-2001091805-A2 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS | BRACCO RESEARCH USA (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147555-A1 | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same | LDHB, FPGS, MTHFD2 | KMT2A 3035/4885EPHX2 381/4885TLR2 2885/4885 |
| US-20020147136-A1 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | VCAM1, FLT1, EDNRA | KMT2A 4265/4885EPHX2 1498/4885TLR2 755/4885 |
| US-20050027105-A9 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | KMT2A 3846/4885EPHX2 4192/4885TLR2 4510/4885 |
| US-20040018974-A1 | Multivalent constructs for therapeutic and diagnostic applications | CD47, BCR, CD44 | KMT2A 2522/4885EPHX2 1952/4885TLR2 3487/4885 |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | KMT2A 3846/4885EPHX2 4192/4885TLR2 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.